Donafenib demonstrates superior survival benefits and safety compared to sorafenib.
Hepatic arterial infusion chemotherapy (HAIC) proves effective for large unresectable hepatocellular carcinoma (uHCC) over transarterial chemoembolization.
This study aims to investigate the safety and efficacy of combining HAIC with donafenib and sintilimab in patients with uHCC.
